Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Takeda to Shift Immunoglobulin Production to 10% Formulation
Takeda Pharmaceutical said on June 26 that it plans to consolidate the production of its plasma-derived immunoglobulin products into the higher-concentration Kenketu Glovenin-I 10% formulation, following the NHI listing of the upgraded product earlier this month. The company reported the…
To read the full story
Related Article
- Takeda Rolls Out Higher-Concentration Kenketu Glovenin-I 10%
July 7, 2026
- Takeda Wins Approval for Liquid Kenketu Glovenin-I 10%; Overseas-Derived Version Already Launched
February 12, 2026
- Takeda Plans January Rollout of Overseas Plasma-Derived Ig amid Suspension
December 25, 2025
- Takeda Mulls Boost in Imports amid Kenketu Glovenin-I Suspension
November 5, 2025
- Takeda Halts Shipments of Kenketu Glovenin-I to Review Narita Plant Process
November 5, 2025
- Takeda Files Liquid Formulation of IVIg Therapy in Japan
February 17, 2025
REGULATORY
- Provider-Payer Tug-of-War Takes Shape over FY2027 Drug Price Revision
October 8, 2026
- Imulrio Finally Set for NHI Listing after 296-Day Wait; Zero Rule Strikes Again
October 8, 2026
- Japan Panel to Mull Hernexeos 1st-Line Use, Rinvoq Alopecia Expansions
October 8, 2026
- SCARDA, Thai Vaccine Institute Link Up on KM Biologics’ Dengue Shot
October 7, 2026
- MHLW Opens Applications for Innovation Fund’s Ecosystem Program
October 7, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…